Total Payments
$770,250
2024 Payments
$29,847
Companies
25
Transactions
573
Medicare Patients
635
Medicare Billing
$171,930
Payment Breakdown by Category
Other$443,562 (57.6%)
Consulting$228,706 (29.7%)
Travel$88,999 (11.6%)
Food & Beverage$8,983 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $427,762 | 135 | 55.5% |
| Consulting Fee | $228,706 | 87 | 29.7% |
| Travel and Lodging | $88,999 | 214 | 11.6% |
| Honoraria | $15,800 | 4 | 2.1% |
| Food and Beverage | $8,983 | 133 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $121,809 | 85 | $0 (2019) |
| Bayer Healthcare Pharmaceuticals Inc. | $112,539 | 82 | $0 (2023) |
| TAIHO ONCOLOGY, INC. | $87,349 | 74 | $0 (2024) |
| Amgen Inc. | $72,535 | 85 | $0 (2024) |
| Celgene Corporation | $67,295 | 52 | $0 (2019) |
| Merck Sharp & Dohme LLC | $62,166 | 34 | $0 (2023) |
| Seagen Inc. | $53,335 | 34 | $0 (2023) |
| PFIZER INC. | $46,943 | 29 | $0 (2024) |
| ARRAY BIOPHARMA INC | $27,425 | 14 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $20,449 | 17 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,847 | 19 | PFIZER INC. ($17,788) |
| 2023 | $128,403 | 70 | Seagen Inc. ($43,601) |
| 2022 | $63,651 | 43 | AstraZeneca Pharmaceuticals LP ($14,678) |
| 2021 | $38,993 | 21 | Daiichi Sankyo Inc. ($11,273) |
| 2020 | $77,866 | 62 | Taiho Oncology, Inc. ($36,324) |
| 2019 | $128,531 | 79 | Bayer HealthCare Pharmaceuticals Inc. ($29,946) |
| 2018 | $145,815 | 137 | Genentech USA, Inc. ($57,185) |
| 2017 | $157,143 | 142 | Genentech USA, Inc. ($47,812) |
All Payment Transactions
573 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Amgen Inc. | Vectibix (Biological) | Consulting Fee | Cash or cash equivalent | $1,298.00 | General |
| Category: Oncology | ||||||
| 06/12/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 05/03/2024 | PFIZER INC. | BRAFTOVI (Drug) | Travel and Lodging | In-kind items and services | $78.14 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2024 | PFIZER INC. | BRAFTOVI (Drug) | Food and Beverage | In-kind items and services | $11.68 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | PFIZER INC. | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,625.00 | General |
| Category: ONCOLOGY | ||||||
| 04/22/2024 | Amgen Inc. | Vectibix (Biological) | Consulting Fee | Cash or cash equivalent | $649.00 | General |
| Category: Oncology | ||||||
| 04/18/2024 | Intera Oncology, Inc | INTERA (Device) | Food and Beverage | In-kind items and services | $67.36 | General |
| Category: ONCOLOGY | ||||||
| 04/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Consulting Fee | Cash or cash equivalent | $435.00 | General |
| Category: ONCOLOGY | ||||||
| 04/03/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Consulting Fee | Cash or cash equivalent | $6,650.00 | General |
| Category: Oncology | ||||||
| 03/21/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,400.00 | General |
| Category: Oncology | ||||||
| 03/21/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $635.21 | General |
| Category: Oncology | ||||||
| 03/21/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $452.20 | General |
| Category: Oncology | ||||||
| 03/21/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $381.60 | General |
| Category: Oncology | ||||||
| 03/21/2024 | PFIZER INC. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $103.52 | General |
| Category: Oncology | ||||||
| 03/21/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $64.00 | General |
| Category: Oncology | ||||||
| 03/21/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $26.80 | General |
| Category: Oncology | ||||||
| 03/21/2024 | PFIZER INC. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $10.27 | General |
| Category: Oncology | ||||||
| 03/11/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $660.00 | General |
| Category: Oncology | ||||||
| 02/05/2024 | Amgen Inc. | Vectibix (Biological) | Consulting Fee | Cash or cash equivalent | $649.00 | General |
| Category: Oncology | ||||||
| 12/22/2023 | Astellas Pharma US Inc | — | Consulting Fee | Cash or cash equivalent | $6,375.00 | General |
| 12/22/2023 | Astellas Pharma US Inc | — | Travel and Lodging | Cash or cash equivalent | $13.00 | General |
| 12/19/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,466.00 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2023 | AVEO Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $410.00 | General |
| 11/09/2023 | Seagen Inc. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,000.00 | General |
| Category: Oncology | ||||||
| 11/09/2023 | Seagen Inc. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $461.35 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 123 | 319 | $104,829 | $36,375 |
| 2022 | 7 | 184 | 489 | $158,097 | $57,341 |
| 2021 | 4 | 171 | 450 | $144,698 | $51,787 |
| 2020 | 7 | 157 | 297 | $85,910 | $26,427 |
Total Patients
635
Total Services
1,555
Medicare Billing
$171,930
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 52 | 229 | $78,694 | $28,031 | 35.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 38 | 53 | $13,510 | $4,184 | 31.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 21 | 21 | $10,245 | $3,395 | 33.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 12 | 16 | $2,380 | $764.79 | 32.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 58 | 327 | $110,526 | $41,285 | 37.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 34 | 34 | $16,354 | $5,651 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 42 | 64 | $16,064 | $5,201 | 32.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $5,346 | $1,782 | 33.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 18 | $4,500 | $1,564 | 34.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 16 | 20 | $2,712 | $1,030 | 38.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 15 | $2,595 | $826.47 | 31.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 62 | 269 | $90,922 | $33,638 | 37.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 51 | 122 | $30,622 | $10,039 | 32.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 44 | 44 | $21,219 | $7,327 | 34.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 14 | 15 | $1,935 | $782.96 | 40.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 43 | 126 | $31,626 | $8,759 | 27.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 32 | 74 | $25,012 | $7,260 | 29.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 21 | 21 | $10,206 | $3,834 | 37.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 18 | 18 | $8,658 | $2,755 | 31.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 18 | $4,500 | $1,691 | 37.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 12 | 17 | $2,941 | $1,108 | 37.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 18 | 23 | $2,967 | $1,021 | 34.4% |
About John Marshall
John Marshall is a Hematology & Oncology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1316935844.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, John Marshall has received a total of $770,250 in payments from pharmaceutical and medical device companies, with $29,847 received in 2024. These payments were reported across 573 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($427,762).
As a Medicare-enrolled provider, Marshall has provided services to 635 Medicare beneficiaries, totaling 1,555 services with total Medicare billing of $171,930. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Washington, DC
- Active Since 10/10/2005
- Last Updated 03/09/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1316935844
Products in Payments
- Avastin (Biological) $126,173
- Lonsurf (Drug) $78,542
- Stivarga (Drug) $73,557
- TUKYSA (Drug) $65,020
- Vectibix (Biological) $64,834
- Abraxane (Drug) $62,278
- BRAFTOVI (Drug) $44,579
- KEYTRUDA (Biological) $33,409
- IMFINZI (Biological) $15,044
- Vitrakvi (Drug) $14,708
- FRUZAQLA (Drug) $11,885
- Enhertu (Drug) $9,575
- SIR-Spheres Microspheres (Device) $9,167
- ONIVYDE (Drug) $8,863
- LONSURF (Drug) $8,807
- KRAZATI (Drug) $6,650
- Lenvima (Drug) $5,128
- Nexavar (Drug) $4,550
- YONSA (Drug) $3,492
- Onivyde (Drug) $3,150
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Washington
Imad Tabbara, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Dr. Catherine Broome, Md, MD
Hematology & Oncology — Payments: $693,161
Hematology & Oncology $693,161
Craig Kessler
Hematology & Oncology — Payments: $632,186
Hematology & Oncology $632,186
Claudine Isaacs
Hematology & Oncology — Payments: $406,847
Hematology & Oncology $406,847
Muhammad Mirza, M.d, M.D
Hematology & Oncology — Payments: $118,419
Hematology & Oncology $118,419
Dr. Christopher Gallagher, M.d, M.D
Hematology & Oncology — Payments: $107,252
Hematology & Oncology $107,252